This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Generalized Pustular Psoriasis전신농포건선

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: L40.1 | Special Copayment Reduction: V313 (rare disease)
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood: high — generalized pustular psoriasis (von Zumbusch type) occurs mainly in adults in their 30s to 50s, and often develops as an abrupt exacerbation in patients with a history of plaque psoriasis. The pediatric form (DITRA) occurs in childhood and has a genetic basis distinct from the adult form.
1. History

Generalized pustular psoriasis (GPP) is a severe rare variant of psoriasis distinct from plaque psoriasis, across the skin…

2. Causes

The pathogenesis of generalized pustular psoriasis is explained largely by the combined action of genetic predisposition and environmental triggers. At the molecular level, …of the IL-36 signaling pathway

3. Genetics

The genetics of generalized pustular psoriasis has advanced rapidly in recent years. Loss-of-function mutations (p.… in the IL36RN (9p21.3) gene

4. General epidemiology

Generalized pustular psoriasis is a rare disease, and data on its exact incidence and prevalence are limited. In a Japanese epidemiological study, the prevalence was about 7… per million population

5. Pathophysiology

The core pathophysiology of generalized pustular psoriasis is dysregulation of the IL-36 signaling pathway and massive migration of neutrophils into the skin.…

6. Symptoms

Acute flares of generalized pustular psoriasis have an abrupt course and can spread throughout the body within hours to days, so they must be managed as an emergency…

7. Signs

The most characteristic physical sign of generalized pustular psoriasis is sterile pustules arising on an erythematous background. The pustules are…in diameter

8. Screening

The diagnosis of generalized pustular psoriasis is based mainly on clinical findings, and serum and skin biopsy tests confirm the diagnosis. Rapidly developing widespread sterile pustules and fever…

9. Diagnosis

The diagnosis of generalized pustular psoriasis refers to the 2018 diagnostic criteria of the European Reference Network for rare skin diseases (ERN-Skin) and the Japanese Dermatological Association. The core…

10. Treatment

Treatment of generalized pustular psoriasis is divided into treatment of acute flares and long-term maintenance of remission. An acute flare is an emergency, and inpatient treatment, fluid and electrolyte correction, fever management,…

11. Prognosis

The prognosis of generalized pustular psoriasis depends on the severity of flares, underlying health status and whether triggers are eliminated. Mortality from appropriately treated acute flares has decreased…

12. Prevention

The key to preventing recurrence of generalized pustular psoriasis is eliminating triggers and long-term maintenance treatment. Avoid abrupt tapering or discontinuation of systemic steroids, and contraindicated in psoriasis…

13. References10 papers in major international journals.

1. History

Generalized pustular psoriasis (GPP) is a severe rare variant of psoriasis distinct from plaque psoriasis, characterized by the abrupt development of sterile pustules across the skin. Historically, in 1910 the Austrian dermatologist Leo von Zumbusch first described a severe variant of psoriasis in which numerous pustules develop on erythematous skin accompanied by systemic symptoms, giving rise to the name 'von Zumbusch type pustular psoriasis'.

Until the mid-20th century, generalized pustular psoriasis was regarded as a variant of severe psoriasis, but as immunological studies in the 1970s–90s elucidated T cell-mediated immune responses and neutrophil recruitment mechanisms, it began to be recognized as an independent disease entity. Genomic studies in 2011 and later confirmed that IL36RN (interleukin-36 receptor antagonist gene) mutations are associated with DITRA (deficiency of the IL-36 receptor antagonist) syndrome and pediatric generalized pustular psoriasis. This discovery revealed the IL-36 signaling pathway as the core pathogenesis of generalized pustular psoriasis and led directly to the development of therapeutic targets.

In 2021, spesolimab (an anti-IL-36 receptor monoclonal antibody) received FDA Breakthrough Therapy designation, and in 2022 it received FDA approval for the treatment of GPP acute flares, bringing a fundamental change in the treatment paradigm. In 2023, clinical trials were also under way for other IL-36 pathway-blocking therapies such as inaebilizumab. In Korea, GPP is classified as an ultra-rare disease, and there are reports that the frequency of IL36RN variants is somewhat higher in East Asia, including Japan and China, than in Western countries.

2. Causes

The pathogenesis of generalized pustular psoriasis is explained largely by the combined action of genetic predisposition and environmental triggers. At the molecular level, hyperactivation of the IL-36 signaling pathway has been established as the core mechanism. IL-36α, IL-36β and IL-36γ bind to the IL-36 receptor (IL-36R) and, via the NF-κB and MAPK pathways, induce secretion of potent proinflammatory cytokines (IL-17, IL-8/CXCL8, IL-1β, TNF-α) from keratinocytes and immune cells. IL-36RA (receptor antagonist) normally inhibits IL-36 signaling. When there are loss-of-function mutations in the IL36RN gene (the gene encoding IL-36RA), IL-36 signaling is not inhibited, resulting in IL-36-mediated excessive neutrophil recruitment and pustule formation in the skin.

Environmental triggers known to provoke acute GPP flares include rapid tapering or discontinuation of systemic steroids, pregnancy (pustular psoriasis of pregnancy, impetigo herpetiformis), hypocalcemia, local irritation (rebound after excessive topical steroid use), infection and certain drugs (lithium, hydroxychloroquine, β-blockers). These triggers directly or indirectly activate the IL-36 pathway, disrupting the already fragile balance of IL-36 regulation.

3. Genetics

The genetics of generalized pustular psoriasis has advanced rapidly in recent years. Loss-of-function mutations in the IL36RN (9p21.3) gene (p.Leu27Pro, p.Thr123Met, p.Arg48Trp, etc.) have been identified as the most important single-gene cause in patients with DITRA syndrome and in pediatric and adult GPP patients. IL36RN variants are detected in about 20–30% of GPP patients, with a higher frequency (about 30–50%) reported in East Asian patients. Inheritance is autosomal recessive, and homozygous or compound heterozygous variants cause DITRA. Other genes reported as GPP-related include CARD14 gain-of-function variants (CAMPS, CARD14-mediated pustular psoriasis), AP1S3 variants (endoplasmic reticulum stress-mediated) and MPO variants. Because no specific single-gene variant is identified in most adult GPP patients, a complex genetic background is assumed.

4. General epidemiology

Generalized pustular psoriasis is a rare disease, and data on its exact incidence and prevalence are limited. In a Japanese epidemiological study, the prevalence was reported to be about 7.5 per million population. Lower prevalence is estimated in Europe and North America, but systematic studies are lacking. There is evidence that IL36RN variant-related GPP accounts for a relatively high proportion in East Asia, including Korea. Age at onset shows a bimodal distribution, concentrated in childhood (DITRA-related, first decade) and adulthood (30s–50s). Pustular psoriasis of pregnancy (impetigo herpetiformis) is the pregnancy variant of GPP and occurs in late pregnancy. The risk of conversion to GPP in patients with plaque psoriasis is estimated at about 1–2%. Epidemiological studies using health insurance data have been conducted in Korea, and some domestic characteristics have been reported.

5. Pathophysiology

The core pathophysiology of generalized pustular psoriasis is dysregulation of the IL-36 signaling pathway and massive migration of neutrophils into the skin. Under normal conditions, keratinocytes secrete small amounts of IL-36 cytokines in response to infection or injury, and IL-36RA inhibits them in balance. In GPP, when IL-36RA function is lost or IL-36 signaling is upregulated, IL-36α and γ are oversecreted by keratinocytes, forming an autocrine amplification loop. IL-36 signaling induces keratinocytes to secrete CXC chemokines such as CXCL1 and CXCL8, which recruit neutrophils into the skin on a massive scale. Neutrophils that migrate into the epidermis form sterile pustules, and neutrophil activation products (proteases, reactive oxygen species) further damage keratinocytes, further increasing IL-36 secretion in a vicious cycle.

IL-17A and IL-17F also contribute importantly to GPP pathogenesis. IL-17 secreted by Th17 cells and γδ T cells amplifies IL-36 secretion and production of neutrophil-attracting chemokines in keratinocytes. TNF-α and IL-1β also contribute to this inflammatory network and act in mutual reinforcement with IL-36 signaling. The systemic inflammatory response manifests as fever, leukocytosis, elevated CRP and hypoalbuminemia, and in severe cases may progress to a sepsis-like state that can be life-threatening.

6. Symptoms

Acute flares of generalized pustular psoriasis have an abrupt course and can spread throughout the body within hours to days, so they must be managed as an emergency. Initial symptoms are preceded by generalized malaise, fever (38–40°C), and skin pain and burning. Then hundreds to thousands of small (1–3 mm) sterile pustules develop rapidly on widespread erythematous skin. The pustules coalesce to form 'lakes of pus', and after drying, erosions covered with yellow-brown scales are exposed. A pattern of repeated vesicular, pustular, drying and desquamative phases is seen. With systemic involvement, electrolyte abnormalities (hypocalcemia, hypoalbuminemia), secondary infection, sepsis, heart failure and liver dysfunction may accompany it.

Pustular psoriasis of pregnancy occurs in late pregnancy (third trimester) and carries risks of placental insufficiency and fetal death, requiring urgent obstetric evaluation. Pediatric DITRA presents from the first few months of life with recurrent pustular flares and fever, and repeated hospitalizations and growth retardation may occur. Joint symptoms (psoriatic arthritis) accompany it in about 30–50%, and geographic tongue of the oral mucosa is also common.

7. Signs

The most characteristic physical sign of generalized pustular psoriasis is sterile pustules arising on an erythematous background. The pustules are yellow-white papules 1–3 mm in diameter that tend to cluster on erythematous skin rather than on normal skin. Lesions at various stages (fresh pustules, dried pustules, scales, erosions) coexist across the skin. Body temperature rises to 38–40°C or higher, general condition is poor, and signs of dehydration and electrolyte abnormalities (muscle cramps, tetany) may accompany it. Peripheral blood tests show marked neutrophilia, elevated CRP and ESR, hypoalbuminemia and hypocalcemia. On skin biopsy, sterile intraepidermal pustules (spongiform pustules, spongiform pustules of Kogoj) and neutrophil infiltration are characteristic. Negative bacterial culture of the pustules (sterile) is essential for the diagnosis of GPP.

8. Screening

The diagnosis of generalized pustular psoriasis is based mainly on clinical findings, and serum and skin biopsy tests confirm the diagnosis. GPP should be suspected first in patients with rapidly developing widespread sterile pustules and fever. Acute-phase screening tests include a blood count (neutrophilia), electrolytes, calcium, albumin, CRP, ESR, liver function tests, renal function tests and blood cultures. Pustule culture (confirming negative culture) and skin biopsy (histopathology) are essential for confirmation. IL36RN gene analysis is performed especially in patients with pediatric onset, recurrent disease or a family history. Underlying plaque psoriasis and triggers (drugs, infection, pregnancy, hypocalcemia) are assessed at the same time.

9. Diagnosis

The diagnosis of generalized pustular psoriasis refers to the 2018 diagnostic criteria of the European Reference Network for rare skin diseases (ERN-Skin) and the Japanese Dermatological Association. The core diagnostic criteria are: ① acute/recurrent onset of generalized sterile pustules, ② histological intraepidermal pustules (spongiform pustules), ③ negative bacterial culture. Supporting criteria include fever, systemic symptoms, IL36RN mutation and a history of psoriasis. Differential diagnoses include acute generalized exanthematous pustulosis (AGEP), subacute cutaneous lupus erythematosus, inflammatory linear epidermal nevus, alopecic pustular dermatosis of the scalp and infectious pustular skin lesions. AGEP is a drug (antibiotic)-induced pustular eruption similar to GPP, but it resolves rapidly and often lacks IL36RN variants, so it is differentiated by history taking and genetic testing.

10. Treatment

Treatment of generalized pustular psoriasis is divided into treatment of acute flares and long-term maintenance of remission. An acute flare is an emergency, and inpatient treatment, fluid and electrolyte correction, fever management and prevention of secondary infection are fundamental. Spesolimab is an IL-36 receptor-blocking monoclonal antibody approved by the FDA in 2022 for the treatment of acute flares of GPP in adults. In a phase 3 trial (Effisayil-1), the pustule clearance rate after 1 week was 54% (control group 6%). It is used as an intravenous injection (900 mg, with additional doses if needed). Conventional treatments used include acitretin, cyclosporine, infliximab, secukinumab and ixekizumab. In pustular psoriasis of pregnancy, cyclosporine, IVIG and corticosteroids may be used, taking fetal safety into account. Systemic steroids are generally avoided as monotherapy because of the risk of rebound flares.

11. Prognosis

The prognosis of generalized pustular psoriasis depends on the severity of flares, underlying health status and whether triggers are eliminated. Mortality from appropriately treated acute flares has decreased, but deaths from sepsis and multiple organ failure are still reported. The introduction of spesolimab has made rapid relief of acute flares possible. Long-term maintenance treatment to prevent recurrence (acitretin, biologics) can reduce the frequency and severity of flares. Carriers of IL36RN mutations have a strong tendency toward repeated flares, so continuous specialist follow-up is necessary. In pediatric DITRA, developmental delay, growth failure and repeated hospitalizations affect long-term quality of life. When arthropathy is present, early antirheumatic treatment is needed to prevent joint damage.

12. Prevention

The key to preventing recurrence of generalized pustular psoriasis is eliminating triggers and long-term maintenance treatment. Abrupt tapering or discontinuation of systemic steroids is avoided, and drugs contraindicated in psoriasis (lithium, β-blockers, hydroxychloroquine) are avoided. Hypocalcemia, if present, is actively corrected. For long-term maintenance, regular administration of acitretin or biologics (anti-IL-17, anti-IL-12/23, anti-IL-36R) is recommended. In families of pediatric patients with confirmed IL36RN gene mutations, genetic counseling is used to make families aware of the risk of disease in future children and to establish an early detection system. GPP patients planning pregnancy should consult a specialist thoroughly before pregnancy to assess the risk of pustular psoriasis of pregnancy and establish a treatment plan.

13. References

  1. Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the Interleukin-36 Receptor for Generalized Pustular Psoriasis. N Engl J Med. 2021;385(26):2431-2440. DOI: 10.1056/NEJMoa2111563. PMID: 34879190.
  2. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620-628. DOI: 10.1056/NEJMoa1013068. PMID: 21848460.
  3. Choon SE, Lai NM, Mohammad NA, et al. Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol. 2014;53(6):676-684. DOI: 10.1111/ijd.12070. PMID: 24168547.
  4. Fujita H, Gooderham M, Romiti R. Diagnosis and Classification of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13-19. DOI: 10.1007/s40257-021-00652-5. PMID: 35147919.
  5. Hussain S, Berki DM, Choon SE, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(4):1067-1070.e9. DOI: 10.1016/j.jaci.2014.09.043. PMID: 25459619.
  6. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. DOI: 10.1111/jdv.14386. PMID: 28836289.
  7. Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021-1026. DOI: 10.1016/j.jaci.2018.06.038. PMID: 30042022.
  8. Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol. 2011;164(5):942-946. DOI: 10.1111/j.1365-2133.2011.10233.x. PMID: 21320104.
  9. Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919. DOI: 10.1080/1744666X.2019.1648209. PMID: 31355696.
  10. Sugiura K. The genetic background of generalized pustular psoriasis: IL36RN mutations and CARD14 gain-of-function variants. J Dermatol Sci. 2014;74(3):187-192. DOI: 10.1016/j.jdermsci.2014.02.006. PMID: 24656977.